Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BIND Biosciences, Inc. Awarded NIH Phase I SBIR Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy

Abstract:
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles, announced today that it has been awarded a six month $150,000 Phase I SBIR contract from the National Cancer Institute (NCI) to develop a targeted therapy for hormone refractory prostate cancer (HRPC). Prostate cancer accounts for an estimated 27,000 annual deaths in the U.S. and is an area of enormous unmet medical need.

BIND Biosciences, Inc. Awarded NIH Phase I SBIR Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy

Cambridge, MA | Posted on October 8th, 2007

"The NCI SBIR funding is one important validation of BIND's therapeutic targeted nanoparticle platform and will accelerate our prostate cancer program," according to Dr. Jeff Hrkach, Vice President of Pharmaceutical Sciences at BIND and the Principal Investigator on this Phase I SBIR program. "By utilizing BIND's targeted polymeric nanoparticle technology, we will be able to develop revolutionary therapies to address prostate cancer."

"BIND was founded, in-part, based on technologies that were developed through a $20M NCI funded Center for Cancer Nanotechnology Excellence. We view this SBIR contract as a continued collaboration with the NCI as we move toward commercializing breakthrough therapies for important human diseases, including cancer," said Glenn Batchelder, President and Chief Executive Officer of BIND. "We are very fortunate to have Dr. Hrkach leading this program with his extensive expertise in polymeric particle drug delivery and his broad drug development experience accumulated during his tenures at Advance Inhalation Research, Alkermes and Momenta."

The NCI SBIR program is a peer-reviewed competitive funding process that provides research support to companies discovering and developing innovative biomedical products for the treatment and diagnosis of cancer. Companies that successfully meet the goals of this Phase I program are eligible to apply for an additional $1,000,000 in Phase II support to continue their development efforts. This work builds on nanoparticle technologies that were originally developed by BIND's scientific founders, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Brigham and Women's Hospital - Harvard Medical School) and BIND has licensed the large patent estate covering these technologies on a worldwide exclusive basis.

####

About BIND Biosciences, Inc.
BIND Biosciences is a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles. The company’s product-platform leverages the convergence of polymeric biomaterials, nanoparticle engineering and combinatorial synthesis to uniquely enable BIND to design and optimize targeted nanoparticle therapeutics for specific indications. BIND’s technology concentrates drug at the intended site of action while minimizing systemic exposure, thereby improving efficacy and reducing off-target effects.

The company’s platform is broadly applicable across therapeutic areas with the initial product development efforts focused in cancer and cardiovascular disease. The company anticipates initiating clinical trials for their first product in 2009. Founded in 2006 and backed by leading venture capital firms, Flagship Ventures and Polaris Venture Partners, BIND is based in Cambridge, Massachusetts.

For more information, please click here

Contacts:
BIND Biosciences, Inc.
Glenn Batchelder, President and CEO, 617-491-3400

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Govt.-Legislation/Regulation/Funding/Policy

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014

Nanomedicine

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

Announcements

Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014

Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014

Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014

Pressure probing potential photoelectronic manufacturing compound July 31st, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

New imaging agent provides better picture of the gut July 25th, 2014

Hysitron is Awarded TWO R&D 100 Awards for Highly Innovative Technology Developments in the Areas of Extreme Environments and Biological Mechanical Property Testing July 23rd, 2014

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

EPFL Research on the use of AFM based nanoscale IR spectroscopy for the study of single amyloid molecules wins poster competition at Swiss Physics Society meeting July 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE